When: Volume-confirmed close below $172 triggers full breakdown per 8/31 framework

Then: Full exit of position

When: AFFO beat vs consensus + 2027 organic billings guide reaffirmed/upgraded + dividend coverage maintained/expanded + constructive CoreSite/AI commentary

Then: Upgrade to Buy; add 25–50% with stop ratcheted to $174

When: AFFO miss OR softening 2027 guide OR dividend coverage concerns OR CoreSite utilization commentary weakening

Then: Downgrade to Underweight; trim 30–40% with hard stop at $172

HOLD with tighter risk parameters: reduce position 10-15% into earnings catalyst; tighten stop from $172 to $173 (~$1.50 or <1.5% additional room); maintain dry powder for post-confirmation deployment

• Technical support at $172 has been tested 5 times — repeated tests degrade structural integrity, suggesting 'coiled spring' with mounting failure risk rather than strengthening floor
• MACD histogram deteriorated from +1.55 (Aug 25) to -0.10 currently; MACD line at +0.84 converging with signal line at +0.94 — bearish crossover imminent
• CFO trough guidance is management commentary with incentive bias (support stock for cheap equity issuance), not a near-term price catalyst regardless of accuracy
• $1.6 billion debt raise at 5.55% weighted average creates $88.8 million annual incremental interest expense — 'expensive insurance' in zero-cut environment priced at 95% probability
• Goodwill of $26.8 billion against negative $23.1 billion tangible book carries impairment risk (realized: $100M in 2025, $280M in 2023) if AI cycle disappoints or rates rise further
• Aggressive 4:1 reward-risk requires 4 independent bullish scenarios (2027 acceleration, carrier normalization, CoreSite AI capture, rate relief) — downside requires only one failure
• Dividend coverage at 1.20x FCF means 17% FCF decline puts dividend at risk — realistic stress scenario in higher-for-longer environment
• Conservative analyst endorses neutral analyst's 1.5-2:1 risk-reward framing as probability-weighted reality vs. cherry-picked best case
• Position trim ahead of binary earnings catalyst is 'responsible risk management,' not market-timing — preserves dry powder for post-confirmation entry

→ vs aggressive: Entry $173/stop $169/target $188-192 is not 4:1 asymmetric reward — it requires 4 simultaneous bullish catalysts while downside needs only 1 bearish trigger to materialize

→ vs aggressive: MACD -0.10 is not 'noise' — it's a 2-point deterioration in histogram over <1 month from peak +1.55, textbook momentum decay pattern preceding lower prices

→ vs aggressive: $1.6B debt at 5.55% is not 'cheap insurance' — it's $88.8M annual coupon locked in at peak cycle pricing with 95% probability of zero Fed cuts in 2026

→ vs aggressive: Wells Fargo SpaceX thesis is one sell-side opinion, not an information edge — satellite-to-tower cannibalization risk remains plausible in rural/EM use cases

→ vs aggressive: CFO trough guidance cannot be front-run as near-term catalyst — markets can remain mispriced for quarters after fundamental inflection regardless of executive accuracy

→ vs aggressive: Forward P/E of 25x bakes in substantial AI growth — 15-20% capex disappointment triggers multiple compression across data center REIT cohort including AMT

HOLD with refinements: maintain position with stop at $172, define contingent add/trim triggers around Q3 earnings catalyst

• Entry at $179.20 and stop at $172 form a coherent risk framework for the current HOLD position
• Keep stop at $172 (not $173) as it is the structural breakdown level where bear case confirms
• Add 25% of position size if stock closes above $179.20 on above-average volume OR if Q3 print guides to 2027 organic growth re-acceleration with carrier capex visibility; trim 15-20% if organic tenant billings, AFFO guidance, or CoreSite utilization disappoints
• AMT is range-bound between $172 and $179 with volatility compressed to $4 ATR; next major catalyst is 3-4 weeks away
• MACD histogram deterioration from plus 1.55 (August 25) to minus 0.10 is a confirmed momentum shift; bearish crossover with signal line at plus 0.94 is imminent
• Aggressive analyst's 4.75-to-1 risk-reward collapses to approximately 1.5-to-2-to-1 when probability-weighted across four independent bullish scenarios
• Conservative analyst's stop at $173 is counterproductive as it sits above the $172 level that has demonstrated five successful defenses
• Trim at $175 sacrifices potential 2-3 point gap on Q3 trough confirmation; cost of being wrong on trim exceeds cost of being wrong on holding
• Impairment risk ($100M in 2025, $280M in 2023) is overstated for near-term; impairments follow multi-year deterioration not single-trough prints
• AMT fundamentals are solid: revenue grew 5.1% in 2025, free cash flow more than doubled 2022-2025, dividend yield at 3.96% is 50 basis points above 10-year Treasury
• Macro constraints are real: Polymarket shows 95% no-cut probability, 10% recession tail, but idiosyncratic story justifies holding through range
• Dividend coverage at 1.20x with $45B debt against $45B equity base presents balanced risk

→ vs aggressive: Reframing of $172 support tests as institutional floor-building is intellectually appealing but not provable from price action alone; cannot claim five successful defenses as strength while ignoring that marginal seller keeps returning

→ vs aggressive: MACD histogram at minus 0.10 is not noise; two-point deterioration in less than a month with bearish crossover imminent in days not weeks

→ vs aggressive: 4-to-1 risk-reward collapses to 1.5-to-2-to-1 when probability-weighted across four independent scenarios; target of $188-$192 requires macro multiple expansion that Polymarket says is unlikely in 2026

→ vs conservative: Tightening stop from $172 to $173 is backwards; $173 sits in air above structural demand while $172 has demonstrated five successful defenses; stop at $173 more likely to get triggered on noise

→ vs conservative: Trim at $175 ahead of Q3 earnings sacrifices a potential 2-3 point gap if print confirms trough; trim cost exceeds hold cost

→ vs conservative: Goodwill and impairment risk ($10B CoreSite) is overstated for near-term; impairments follow multi-year deterioration not single-trough prints; pricing multi-year tail risk into near-term decision inflates apparent risk